Tag

Mounjaro

All articles tagged with #mounjaro

health8 days ago•12 min saved

Why men are keeping weight-loss injections under wraps

BBC follows comedian Steffen Peddie’s personal use of weight-loss injections (Wegovy) to shed over 8 stone and examines why men discuss such treatments less openly than women. With about 1.6 million adults in England, Wales and Scotland estimated to have used weight-loss drugs in 2024–25 (often bought privately), the piece shares men’s experiences, the stigma and privacy surrounding use, reported side effects, and medical calls for open discussion and routine monitoring to ensure safe, effective use.

via BBC|

#health #men #mounjaro

health12 days ago•48 min saved

19-Year-Old Student Dies After Using Common GLP-1 Weight-Loss Drug

A 19-year-old law student from Corona, California, died in a London dorm after taking tirzepatide, a widely prescribed GLP-1/GIP weight‑loss drug sold as Mounjaro and Zepbound. An inquest found her death was due to cardiac arrhythmia, with doctors noting a congenital heart condition (myocardial bridging) that may have contributed; vomiting could have triggered electrolyte imbalances leading to the arrhythmia. Nasr had been prescribed Zepbound by a U.S. doctor and was not obese, highlighting potential risks associated with GLP-1 therapies.

via Yahoo|

#cardiac-arrhythmia #glp-1-drugs #health

health14 days ago•4 min saved

Mounjaro linked to lower heart attack risk in diabetics with heart disease

An observational study of about 53,000 people with type 2 diabetes and established heart disease found tirzepatide (Mounjaro) was associated with a 33% lower risk of major cardiovascular events, including heart attack, over roughly one year compared with sitagliptin; 2.9% vs 4.4% event rates, roughly one event prevented per 70 new tirzepatide users. The findings add to evidence GLP-1 meds may support heart health, but the study’s observational design and short follow-up limit conclusions, and tirzepatide is not FDA-approved for cardiac risk reduction.

via Healthline|

#glp-1 #health #heart-attack

business20 days ago•4 min saved

Lilly widens GLP-1 lead as Novo's growth path faces questions

Eli Lilly beat estimates again, lifted full-year guidance, and extended its lead in the GLP-1 obesity/diabetes market with strong demand for Mounjaro and Zepbound, sending the stock higher. Novo Nordisk also beat and raised guidance but faced investor skepticism over its growth trajectory after Wegovy missed expectations, mixed results for its experimental CagriSema, and concerns about pipeline diversification. The market remains bifurcated: Lilly is seen as the momentum winner, while Novo grapples with turning around its growth story despite European expansion and Wegovy's continued rollout, including a September German launch.

via CNBC|

#business #eli-lilly #glp-1

business21 days ago•3 min saved

Lilly rides GLP-1 wave, lifts 2026 outlook on Zepbound/Mounjaro demand

Eli Lilly beat Q2 estimates as demand for obesity and diabetes drugs fueled stronger earnings, prompting a raise in 2026 revenue guidance to $85–$87 billion. Q2 revenue was $22.97 billion with adjusted EPS of $8.38; Mounjaro worldwide sales reached $9.94 billion, Zepbound US sales were $4.93 billion, and Foundayo contributed $98 million in its first quarter of selling. International sales surged while price cuts trimmed some gains. The company highlighted ongoing aggressive M&A activity and expected benefits from Medicare coverage for obesity drugs.

via CNBC|

#2026-guidance #business #foundayo

business21 days ago•20 min saved

Lilly lifts 2026 outlook on GLP-1 momentum and pipeline expansion

Lilly reported Q2 2026 revenue of $23.0B, up 48% from a year earlier driven by Mounjaro and Zepbound, with GAAP EPS of $7.94 and non-GAAP EPS of $8.38; the company raised its full-year guidance to $85-87B in revenue and $35.50-$36.50 in non-GAAP EPS (midpoint up about $2.78) offset by $3.03 of acquired IPR&D charges, and highlighted regulatory wins (EBGLYSS for atopic dermatitis, Jaypirca in the EU for CLL) and continued obesity pipeline progress (retatrutide) with a planned BLA in 1Q 2027; Lilly also completed multiple acquisitions and announced additional investments to expand manufacturing in Indiana, underscoring a broad, growing pipeline.

via Eli Lilly and Company|

#business #lilly #mounjaro

entertainment23 days ago•49 min saved

Amy Schumer Flaunts Unfiltered Bikini Pics After Year on Mounjaro

Amy Schumer posted a series of unfiltered bikini photos on Instagram on Aug. 1, sharing her ongoing weight‑loss journey after more than a year on Mounjaro. She has previously discussed trying other weight‑loss drugs like Ozempic, undergoing liposuction, and addressing a Cushing syndrome diagnosis, noting she lost about 50 pounds—part of her broader, real‑talk discussion about body image and health.

via buzzfeed.com|

#amy-schumer #entertainment #instagram

entertainment23 days ago•16 min saved

Amy Schumer debuts 50-pound weight loss in unfiltered bikini yacht photos

Comedian Amy Schumer posted unfiltered Instagram photos from a yacht showing a dramatic weight loss (over 50 pounds) after starting Mounjaro to treat Cushing syndrome. The pictures feature her in a wetsuit, a floral bikini, and scuba diving, with supportive comments from friends; she has discussed divorce from Chris Fischer and has said the weight loss was not a cry for help.

via Page Six|

#amy-schumer #bikini-photos #cushing-syndrome

entertainment23 days ago•13 min saved

Amy Schumer Flaunts No-Filter Bikini Glow After Weight-Loss Journey

Amy Schumer posted unfiltered yacht photos showing off her figure after a weight-loss journey she attributes to treating Cushing syndrome and using Mounjaro, after previously trying Wegovy. She says she’s lost about 50 pounds, feels better, has more energy, and enjoyed activities like scuba diving on vacation.

via E! News|

#amy-schumer #bikini #entertainment

entertainment23 days ago•8 min saved

Amy Schumer flaunts weight-loss progress with unfiltered bikini snaps

Comedian Amy Schumer posted unfiltered bikini photos to showcase her weight-loss progress, detailing her journey with diabetes drugs, including Mounjaro after previously trying Ozempic and Wegovy and experiencing severe nausea due to a genetic predisposition, and noting health steps like perimenopause hormone therapy and a past Cushing syndrome diagnosis.

via Fox News|

#amy-schumer #entertainment #mounjaro

health1 month ago•3 min saved

Australia flags rare eye risk tied to GLP-1 diabetes/weight drugs

Australia’s TGA warns of a rare but serious eye disorder called NAION linked to GLP-1 medicines such as Ozempic, Wegovy and Mounjaro; 36 cases have been reported (23 with Ozempic/Wegovy, 10 with Mounjaro, 3 with Saxenda), prompting updated safety warnings but no prescription restrictions. Patients should seek urgent medical attention for sudden vision loss, while doctors are advised not to stop treatment without consultation. Novo Nordisk says the benefit–risk profile remains favorable given the drugs’ overall impact on diabetes and obesity.

via The Guardian|

#glp-1 #health #mounjaro

health1 month ago•8 min saved

GLP-1 Meds May Trigger Rare Hair Loss, Study Finds

A BMJ study links GLP-1 diabetes/weight‑loss meds (semaglutide and tirzepatide) to a small but higher risk of non-scarring hair loss (alopecia) compared with SGLT-2 or DPP-4 therapies. After roughly 2.7 years, GLP-1 users had about 37% higher odds than SGLT-2 and 68% higher than DPP-4, with absolute rates of about 3–9 cases per 1,000 people per year. Hair shedding is usually non-permanent and may reflect telogen effluvium triggered by rapid weight loss or nutrient gaps; while the benefits of GLP-1 drugs remain substantial, patients should be aware of this potential trade-off and monitor for hair changes.

via The Daily Beast|

#alopecia #glp-1 #hair-loss

science1 month ago•13 min saved

Hair loss linked to GLP-1 weight-loss drugs in new study

A BMJ study of about 50,000 people finds GLP-1 receptor agonists (used for diabetes and obesity, including Wegovy, Ozempic and Mounjaro) are associated with a higher risk of hair loss compared with other diabetes drugs; after adjustment, risk was 37% higher than SGLT-2 inhibitors and 68% higher than DPP-4 inhibitors, with indications that the hair loss is non-scarring and may relate to weight loss, micronutrient deficiencies, or hormonal changes; regulators are reviewing safety signals.

via The Independent|

#glp-1 #hair-loss #mounjaro

health2 months ago•4 min saved

GLP-1 Meds Could Muffle Your Senses: Taste and Smell Changes Linked to Ozempic and Mounjaro

A JAMA Network study using electronic health records of adults with type 2 diabetes found that GLP-1 medications such as Ozempic and Mounjaro are associated with a higher risk of smell and taste disturbances, including anosmia, parosmia, and parageusia. The authors suggest these effects may be due to GLP-1 interactions with the nervous system; weight loss common with these drugs can also influence taste and smell. While changes often improve as weight stabilizes, the study calls for closer monitoring and more research. Consult a clinician if you notice sensory changes.

via New York Post|

#glp-1 #health #mounjaro

entertainment3 months ago•2 min saved

Rosie O'Donnell Reveals Subtle Facelift After Weight-Loss Shift

Rosie O'Donnell disclosed in a Substack essay that she underwent a lower deep plane facelift in January and shared before-and-after photos. She says losing 50 pounds on the weight‑loss drug Mounjaro prompted a shift in her views on cosmetic surgery, and that the procedure left her looking and feeling more rested without changing who she is—despite little external notice—and it led her to question rigid feminist ideas about aging.

via TODAY.com|

#entertainment #facelift #feminism